Fresenius: Jefferies raises target price

(CercleFinance.com) - In a report on the German healthcare group Fresenius and its dialysis subsidiary (in the process of being deconsolidated) Fresenius Medical Care, Jefferies confirms its "buy" rating on the former, raising its target price from E38 to E41.


The broker justifies this upgrade by increasing its short-term EPS expectations by 10%-15%, following a solid H1 publication for its operating subsidiaries (Kabi and Helios), as well as by raising the target price for Fresenius MedCare from E21 to E29.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.